Abivax SA (ABVX) Stock Price, News & Analysis

Abivax SA (ABVX) is a clinical-stage biotechnology company in the healthcare sector. According to the company’s disclosures, Abivax focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company describes itself as being based in France and the United States and is listed on both Euronext Paris and Nasdaq under the symbol ABVX.

Abivax’s lead drug candidate is obefazimod (ABX464). Company materials state that obefazimod is being evaluated in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease affecting the colon. The ABTECT Phase 3 program includes 8‑week induction trials and a 44‑week double‑blind maintenance trial in UC. Abivax has reported that the ABTECT Phase 3 induction trials met their primary and key secondary endpoints at the 50 mg once‑daily dose and that a Data Safety Monitoring Board review of the maintenance study found no new safety signals with a large majority of participants completing the 44‑week maintenance phase.

Beyond ulcerative colitis, Abivax states that its initial focus is on inflammatory bowel diseases (IBD), which include UC and Crohn’s disease (CD). The company is conducting the ENHANCE‑CD Phase 2b induction trial of obefazimod in patients with moderate‑to‑severely active Crohn’s disease. Company communications also highlight preclinical data suggesting anti‑fibrotic activity of obefazimod in models of inflammatory bowel disease and note that fibrosis is a serious complication, particularly in Crohn’s disease.

Abivax describes obefazimod as having a first‑in‑class mechanism of action that targets the site of inflammation and is associated with enhancement of miR‑124 expression and downregulation of pro‑inflammatory cytokines such as IL‑17A and IL‑6 in patients with moderate‑to‑severely active UC, based on data from the ABTECT Phase 3 induction trials and related analyses. The company reports that obefazimod has shown clinical activity across a wide range of UC patient subpopulations, including those with and without prior inadequate response to advanced therapies, and that treatment has been well tolerated in the Phase 3 induction setting with no new safety signals identified for the doses studied.

Company updates emphasize that Abivax is building a scientific and clinical evidence base around obefazimod in IBD. Numerous abstracts, including oral, digital oral, and poster presentations, have been accepted at major gastroenterology and IBD meetings such as the United European Gastroenterology (UEG) Congress and the European Crohn’s and Colitis Organization (ECCO) Congress. These presentations cover topics including efficacy and safety in Phase 3 UC induction trials, subgroup analyses by prior therapy exposure and baseline disease characteristics, patient‑reported outcomes, biomarker changes, and preclinical anti‑fibrotic findings.

From a capital markets perspective, Abivax is identified in company announcements as a constituent of key indices and sector benchmarks. The company has stated that it will be added to the Nasdaq Biotechnology Index (NBI) and that it has been admitted to the CAC Mid 60 and SBF 120 indices on Euronext Paris. Abivax has also reported completing an underwritten public offering of American Depositary Shares under an automatic shelf registration statement on Form F‑3, with the ADSs each representing one ordinary share of the company.

Abivax’s public communications and SEC filings describe it as a dual‑listed public company that uses its financial resources primarily to advance research and development, particularly the clinical programs for obefazimod in ulcerative colitis and Crohn’s disease, as well as related preclinical and mechanistic work. The company also reports engaging in activities such as analyst and investor calls, scientific symposia at medical congresses, and the preparation of regulatory submissions related to its clinical programs.

Business focus and therapeutic area

According to repeated “About Abivax” statements in press releases, Abivax’s core business focus is on chronic inflammatory diseases. The company highlights inflammatory bowel disease, especially ulcerative colitis and Crohn’s disease, as its primary therapeutic area. Its development strategy centers on modulating the immune response through the body’s natural regulatory pathways, aiming to stabilize inflammation in chronic conditions.

Lead program: obefazimod in ulcerative colitis

Obefazimod (ABX464) is described as Abivax’s lead drug candidate. Company disclosures state that obefazimod is in Phase 3 clinical trials for moderately to severely active ulcerative colitis. The ABTECT program includes:

• Two randomized, double‑blind, placebo‑controlled, 8‑week induction trials (ABTECT‑1 and ABTECT‑2) in adult UC patients, including individuals with prior inadequate response to advanced therapies.
• A 44‑week double‑blind maintenance trial designed to assess longer‑term outcomes following induction therapy.

Abivax has reported that the 50 mg once‑daily dose of obefazimod met the FDA primary endpoint of clinical remission at Week 8 in both ABTECT‑1 and ABTECT‑2 and that all key secondary efficacy endpoints were met in these induction trials. The company also notes that pooled analyses show clinically meaningful improvements in clinical response and remission across subgroups, including patients with prior inadequate response to multiple lines of advanced therapy, such as JAK inhibitors.

Development in Crohn’s disease and fibrosis

In addition to ulcerative colitis, Abivax is evaluating obefazimod in Crohn’s disease. The ENHANCE‑CD Phase 2b induction trial is designed to assess the safety and efficacy of obefazimod in patients with moderate‑to‑severely active Crohn’s disease. Company announcements also describe preclinical work in fibrotic models of inflammatory bowel disease, with an oral presentation titled “Obefazimod shows first evidence of anti‑fibrotic activity in preclinical models of inflammatory bowel disease” accepted at the ECCO Congress. These preclinical data are presented as addressing fibrosis, a serious complication in Crohn’s disease.

Scientific and clinical evidence base

Abivax emphasizes the breadth of clinical and preclinical data being generated for obefazimod. At the ECCO 2026 Congress, the company reports that 22 abstracts were accepted, including one oral presentation, multiple digital oral presentations, and numerous posters. Topics include:

• Pooled analyses of efficacy and safety from the ABTECT Phase 3 induction trials in UC.
• Subgroup analyses based on baseline disease extent, disease duration, prior inadequate response to advanced therapies, geographic regions, age, and body mass index.
• Patient‑reported outcomes such as bowel urgency, nocturnal bowel movements, fatigue, quality of life, and work productivity.
• Biomarker and mechanistic data, including miR‑124 expression and reductions in IL‑17A and IL‑6.
• Preclinical anti‑fibrotic activity in in vitro and in vivo models of inflammatory bowel disease.

These data are presented in company communications as supporting obefazimod’s clinical activity, tolerability profile, and mechanistic framework in inflammatory bowel disease.

Capital markets and regulatory disclosures

Abivax files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, including Form 6‑K current reports. One Form 6‑K describes an underwriting agreement for a public offering of American Depositary Shares under an automatic shelf registration statement on Form F‑3. Company financial updates highlight that Abivax allocates substantial operating expenses to research and development, particularly its ulcerative colitis and Crohn’s disease clinical programs and related studies.

Index announcements state that Abivax has been selected for inclusion in the Nasdaq Biotechnology Index and in Euronext Paris indices such as the CAC Mid 60 and SBF 120. The company characterizes these inclusions as milestones that increase its visibility within the biotechnology investment community.

Geographic footprint

In its “About Abivax” sections, the company states that it is based in France and the United States. It also notes that its ordinary shares trade on Euronext Paris and that its American Depositary Shares trade on Nasdaq. These disclosures indicate that Abivax operates as a dual‑listed biotechnology issuer with activities in both Europe and North America.